Editorial comment on: Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette-Guérin.
Gofrit
Ofer N
ON
D000283:Administration, Intravesical; D001500:BCG Vaccine / Q000008:administration & dosage*; D014408:Biomarkers, Tumor / Q000032:analysis*; D002277:Carcinoma / Q000737:chemistry / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D049109:Cell Proliferation; D003598:Cytoskeletal Proteins / Q000032:analysis*; D018450:Disease Progression; D018572:Disease-Free Survival; D006801:Humans; D007150:Immunohistochemistry; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D046888:Tissue Array Analysis; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000737:chemistry / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D019459:Urothelium / Q000737:chemistry / Q000473:pathology; D000099149:Ezrin
D001500:BCG Vaccine; D014408:Biomarkers, Tumor; D003598:Cytoskeletal Proteins; D000099149:Ezrin